These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 19293024)
1. Follow: the Raptiva (efalizumab) Pregnancy Registry. Margolis D; Andrews E; Werther W J Am Acad Dermatol; 2009 Apr; 60(4):705. PubMed ID: 19293024 [No Abstract] [Full Text] [Related]
2. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Warren RB; Reich K; Langley RG; Strober B; Gladman D; Deodhar A; Bachhuber T; Bao W; Altemeyer E; Hussain S; Safi J Br J Dermatol; 2018 Nov; 179(5):1205-1207. PubMed ID: 29927479 [No Abstract] [Full Text] [Related]
3. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther; 2003 Dec; 45(1171):97-8. PubMed ID: 14657802 [No Abstract] [Full Text] [Related]
4. [Efalizumab: raptiva]. Descamps V Ann Dermatol Venereol; 2007 Dec; 134(12):982-6. PubMed ID: 18166922 [No Abstract] [Full Text] [Related]
5. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319 [TBL] [Abstract][Full Text] [Related]
6. Efalizumab for the treatment of moderate to severe plaque psoriasis. Jordan JK Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666 [TBL] [Abstract][Full Text] [Related]
8. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169 [TBL] [Abstract][Full Text] [Related]
9. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. Balato A; La Bella S; Gaudiello F; Balato N J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275 [TBL] [Abstract][Full Text] [Related]
10. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Thielen AM; Barde C; Saurat JH Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444 [No Abstract] [Full Text] [Related]
11. [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. Luger T; Reusch M; Reich K; Augustin M; Sterry W J Dtsch Dermatol Ges; 2009 Apr; 7(4):291-2. PubMed ID: 19500192 [No Abstract] [Full Text] [Related]
12. Case reports: practical experience with efalizumab in hand and foot psoriasis. Cohen DJ; Scherschun L J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064 [TBL] [Abstract][Full Text] [Related]
13. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation. Bukhari IA Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804 [TBL] [Abstract][Full Text] [Related]
14. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases. Antonucci A; Bardazzi F; Balestri R; Patrizi A J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361 [TBL] [Abstract][Full Text] [Related]
15. Rebound of psoriasis during treatment with efalizumab. Golda N; Benham SM; Koo J J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294 [TBL] [Abstract][Full Text] [Related]